ReviewClinical and experimental immunology2007
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination.
Review in Clinical and experimental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 53 citations in OpenAlex.
- Article
- Does intention to recommend HPV vaccines impact HPV vaccination rates?Human vaccines & immunotherapeutics · 2014Article
- Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types.The Journal of infectious diseases · 2012Article
- Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.The Journal of infectious diseases · 2012Article
- Multiple human papillomavirus infections and type competition in men.The Journal of infectious diseases · 2012Article
- Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.Journal of clinical microbiology · 2011Article
- MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer.Journal of clinical microbiology · 2011Article
- Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus.Journal of clinical microbiology · 2009Article
- Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role.Cancer · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary cause of cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with more rare cancers, namely cancer of the vulva, vagina, penis, anus, oropharynx and larynx. Effective prophylactic vaccines have been developed. In this review, we briefly address immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most (cost-)effective strategies for cancer control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.